Literature DB >> 17585360

Expression of CD22 on peripheral B cells in patients with rheumatoid arthritis: relation to CD5-positive B cells.

Yutaka Nakiri1, Kentarou Minowa, Jun Suzuki, Akiko Mitsuo, Hirofumi Amano, Shinji Morimoto, Yoshiaki Tokano, Yoshinari Takasaki.   

Abstract

B cells in patients with rheumatoid arthritis (RA) are hyperactivated. Although B cell receptor signal transduction may be affected by various response regulators, CD22 plays an important role as a response regulator of B cells. Therefore, we investigated and examined CD22 expression on peripheral blood B cells of patients with RA. Thirty-two RA patients and 16 controls were enrolled in this study, and CD22 expressions on B cells were analyzed by flow cytometry. In patients with RA, CD22(+) B cells significantly decreased in comparison to the controls (ratio: P < 0.05). However, there was no correlation between this decrease and the clinical data. Interestingly, CD5(+) CD22(-) B cells significantly increased in RA patients. The decrease in CD22(+) B cells and increased in CD5(+)CD22(-) B cells play critical roles in the pathogenesis of RA mediated by the activation of B cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17585360     DOI: 10.1007/s10067-007-0665-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

Review 1.  CD5 B cells, a fetal B cell lineage.

Authors:  R R Hardy; K Hayakawa
Journal:  Adv Immunol       Date:  1994       Impact factor: 3.543

2.  CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice.

Authors:  S Sato; A S Miller; M Inaoki; C B Bock; P J Jansen; M L Tang; T F Tedder
Journal:  Immunity       Date:  1996-12       Impact factor: 31.745

3.  CD22 forms a quaternary complex with SHIP, Grb2, and Shc. A pathway for regulation of B lymphocyte antigen receptor-induced calcium flux.

Authors:  J C Poe; M Fujimoto; P J Jansen; A S Miller; T F Tedder
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

Review 4.  The immunopathology of joint inflammation in rheumatoid arthritis.

Authors:  N J Zvaifler
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

Review 5.  Transmembrane signalling by the B-cell antigen receptor.

Authors:  C J Peaker
Journal:  Curr Opin Immunol       Date:  1994-06       Impact factor: 7.486

6.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

Review 7.  The importance of CD5-positive B cells in nonorgan-specific autoimmune diseases.

Authors:  P Youinou; L Mackenzie; B M Broker; D I Isenberg; A Drogou-Lelong; A Gentric; P M Lydyard
Journal:  Scand J Rheumatol Suppl       Date:  1988

8.  Expression of NKB1 on peripheral T cells in patients with rheumatoid arthritis.

Authors:  Y Nakiri; H Kaneko; S Morimoto; J Suzuki; Y Tokano; H Hashimoto
Journal:  Clin Rheumatol       Date:  2003-10       Impact factor: 2.980

9.  The Leu-1 B-cell subpopulation in patients with rheumatoid arthritis.

Authors:  O Taniguchi; H Miyajima; T Hirano; M Noguchi; A Ueda; H Hashimoto; S Hirose; K Okumura
Journal:  J Clin Immunol       Date:  1987-11       Impact factor: 8.317

10.  Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia.

Authors:  F Caligaris-Cappio; M Gobbi; M Bofill; G Janossy
Journal:  J Exp Med       Date:  1982-02-01       Impact factor: 14.307

View more
  5 in total

1.  Aggressive CD5-positive B-cell lymphoma after remission of CD5-negative follicular lymphoma with distinct immunoglobulin heavy chain rearrangement and translocation.

Authors:  Takashi Sonoki; Sonoko Ishihara; Shima Uneda; Nobuyoshi Hanaoka; Miwa Kurimoto; Hiroshi Matsuoka; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2008-08-30       Impact factor: 2.490

2.  Modulation of B cell regulatory molecules CD22 and CD72 in myasthenia gravis and multiple sclerosis.

Authors:  Jiayin Lu; Jing Li; Tai-qing Zhu; Longbo Zhang; Yuzhong Wang; Fa-fa Tian; Huan Yang
Journal:  Inflammation       Date:  2013-06       Impact factor: 4.092

3.  Atypical phenotype and response of B cells in patients with seropositive rheumatoid arthritis.

Authors:  H Rincón-Arévalo; M Rojas; A Vanegas-García; C Muñoz-Vahos; J Orejuela-Erazo; G Vásquez; D Castaño
Journal:  Clin Exp Immunol       Date:  2021-03-02       Impact factor: 4.330

4.  Comparative proteomic analysis of serum from patients with systemic sclerosis and sclerodermatous GVHD. Evidence of defective function of factor H.

Authors:  Cinzia Scambi; Valentina La Verde; Lucia De Franceschi; Giovanni Barausse; Fabio Poli; Fabio Benedetti; Marco Sorio; Francesca Deriu; Paola Roncada; Oscar Bortolami; Francesco Turrini; Paola Caramaschi; Chiara Stranieri; Lisa M Bambara; Domenico Biasi
Journal:  PLoS One       Date:  2010-08-13       Impact factor: 3.240

5.  Natural autoantibodies reactive with glycosaminoglycans in rheumatoid arthritis.

Authors:  Bence György; László Tóthfalusi; György Nagy; Mária Pásztói; Pál Géher; Zsolt Lörinc; Anna Polgár; Bernadett Rojkovich; Ilona Ujfalussy; Gyula Poór; Péter Pócza; Zoltán Wiener; Petra Misják; Agnes Koncz; András Falus; Edit I Buzás
Journal:  Arthritis Res Ther       Date:  2008-09-12       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.